ProPublica spent 14 months investigating how the Food and Drug Administration regulates foreign drugmakers. We found a system ...
Sign up for The A.V. Club's free newsletter to have the best TV, film, and news stories sent straight to your inbox. If there’s one thing John Oliver does better ...
Recruitment firms publish a steady stream of advice for employers and jobseekers: hiring guides, salary explainers, interview tips and market updates. Those pages can attract useful search traffic, ...
Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home. Credit...Video by Harsha Vadlamani Supported by By Alex Travelli ...
If you take a patented, brand-name medication — a cancer biologic, an autoimmune drug, a specialty injection — the supply chain behind that drug is about to be permanently restructured, starting at 12 ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for ...
President Donald Trump announced Tuesday that imported generic drugs will remain tariff-free for the next two years before facing steep new import duties, saying the move is designed to encourage ...
Federal regulators have agreed to review the applications from Swiss pharmaceutical company Sandoz for two cheaper generic versions of the tirzepatide medications Zepbound and Mounjaro. Eli Lilly’s ...
Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...
TrumpRx now prioritizes generics that comprise ~90% of US prescriptions, shifting from a brand-heavy list toward medications more likely to affect broad population-level out-of-pocket spending.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results